Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cabaletta Bio stock

Own Cabaletta Bio stock in just a few minutes.

Posted

Fact checked

Cabaletta Bio, Inc is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 31 staff and has a market cap (total outstanding shares value) of USD$292.1 million.

How to buy shares in Cabaletta Bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cabaletta Bio. Find the stock by name or ticker symbol: CABA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cabaletta Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cabaletta Bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cabaletta Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cabaletta Bio share price

Use our graph to track the performance of CABA stocks over time.

Cabaletta Bio shares at a glance

Information last updated 2020-10-19.
52-week range USD$5.51 - USD$19.63
50-day moving average USD$10.7982
200-day moving average USD$9.7338
Wall St. target price USD$21.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.9376

Buy Cabaletta Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cabaletta Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cabaletta Bio financials

Gross profit TTM USD$0
Return on assets TTM -16.39%
Return on equity TTM -25.61%
Profit margin 0%
Book value N/A
Market capitalisation USD$292.1 million

TTM: trailing 12 months

Shorting Cabaletta Bio shares

There are currently 1.1 million Cabaletta Bio shares held short by investors – that's known as Cabaletta Bio's "short interest". This figure is 11.1% up from 981,751 last month.

There are a few different ways that this level of interest in shorting Cabaletta Bio shares can be evaluated.

Cabaletta Bio's "short interest ratio" (SIR)

Cabaletta Bio's "short interest ratio" (SIR) is the quantity of Cabaletta Bio shares currently shorted divided by the average quantity of Cabaletta Bio shares traded daily (recently around 104743.03554275). Cabaletta Bio's SIR currently stands at 10.41. In other words for every 100,000 Cabaletta Bio shares traded daily on the market, roughly 10410 shares are currently held short.

However Cabaletta Bio's short interest can also be evaluated against the total number of Cabaletta Bio shares, or, against the total number of tradable Cabaletta Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cabaletta Bio's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cabaletta Bio shares in existence, roughly 50 shares are currently held short) or 0.0568% of the tradable shares (for every 100,000 tradable Cabaletta Bio shares, roughly 57 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cabaletta Bio.

Find out more about how you can short Cabaletta Bio stock.

Cabaletta Bio share dividends

We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.

Cabaletta Bio overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site